HBM Partners — 2022 Investments
1 investments dated 2022 · listed companies and verified rows first · show all
Neuron23neuron23.cominMar 2022 · $100M
Neuron23 is a biotech company using data science, human genetics, and functional genomics to develop precision medicines and companion diagnostics for neurodegenerative diseases, starting with an LRRK2 program for Parkinson's disease.
AI & Machine LearningBiotechDeep TechDigital HealthSouth San Francisco, US
Nancy Stagliano(CEO)in
Co-investorsKleiner PerkinsSoftBank GroupSoftBank Vision FundWestlake Village BioPartnersACORN BIOVENTURESCowen Healthcare Investments+1 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.